$ALZN
Alzamend Neuro, Inc.

2022 Q3 Form 10-Q Financial Statement

#000121465922011092 Filed on September 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2021 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.660M $1.390M
YoY Change 19.41%
% of Gross Profit
Research & Development $1.376M $916.4K
YoY Change 50.15%
% of Gross Profit
Depreciation & Amortization $7.097K $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.376M $2.306M
YoY Change -40.34%
Operating Profit -$3.036M -$2.306M
YoY Change 31.62%
Interest Expense $1.532K -$13.63K
YoY Change -111.24%
% of Operating Profit
Other Income/Expense, Net -$1.532K -$13.63K
YoY Change -88.76%
Pretax Income -$3.037M -$2.320M
YoY Change 30.92%
Income Tax
% Of Pretax Income
Net Earnings -$3.037M -$2.320M
YoY Change 30.92%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03 -$0.03
Diluted Earnings Per Share -$31.16K -$27.43K
COMMON SHARES
Basic Shares Outstanding 95.48M shares
Diluted Shares Outstanding 97.48M shares 84.59M shares

Balance Sheet

Concept 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.53M $15.62M
YoY Change -26.19%
Cash & Equivalents $11.53M $15.62M
Short-Term Investments
Other Short-Term Assets $578.1K $1.183M
YoY Change -51.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.11M $16.82M
YoY Change -27.96%
LONG-TERM ASSETS
Property, Plant & Equipment $95.81K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $95.81K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $12.11M $16.82M
Total Long-Term Assets $95.81K $0.00
Total Assets $12.21M $16.82M
YoY Change -27.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.029M $1.073M
YoY Change -4.09%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $340.1K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.029M $1.473M
YoY Change -30.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.029M $1.473M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.029M $1.473M
YoY Change -30.18%
SHAREHOLDERS EQUITY
Retained Earnings -$32.23M -$19.15M
YoY Change 68.29%
Common Stock $9.548K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.18M $15.34M
YoY Change
Total Liabilities & Shareholders Equity $12.21M $16.82M
YoY Change -27.39%

Cashflow Statement

Concept 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$3.037M -$2.320M
YoY Change 30.92%
Depreciation, Depletion And Amortization $7.097K $0.00
YoY Change
Cash From Operating Activities -$2.537M -$1.223M
YoY Change 107.47%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.91M
YoY Change
NET CHANGE
Cash From Operating Activities -$2.537M -1.223M
Cash From Investing Activities
Cash From Financing Activities 14.91M
Net Change In Cash -$2.537M $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$2.537M -$1.223M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 dei Document Period End Date
DocumentPeriodEndDate
2022-07-31
CY2022Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001677077
CY2022Q3 dei Amendment Flag
AmendmentFlag
false
CY2022Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
CY2022Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
usd
CY2021Q3 alxneuro Conversion Of Series A Convertible Stock
ConversionOfSeriesAConvertibleStock
usd
CY2021Q3 us-gaap Depreciation
Depreciation
usd
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2022Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2022Q3 alxneuro Proceeds From Initial Public Offering Net Of Underwriters Discounts And Commissions And Issuance Costs
ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts
usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q3 alxneuro Fair Value Of Warrants Issued In Connection With Ipo
FairValueOfWarrantsIssuedInConnectionWithIpo
usd
CY2022Q3 alxneuro Fair Value Of Warrants Issued In Connection With March2021 Securities Purchase Agreement Related Party
FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32231569 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3037074 usd
CY2021Q3 us-gaap Other Receivables
OtherReceivables
usd
CY2022Q2 alxneuro Prepaid Insurance1
PrepaidInsurance1
492000 usd
CY2022Q3 alxneuro Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2022Q3 alxneuro Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted
shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022Q3 alxneuro Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross
shares
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q3 alxneuro Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Cancelled Or Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited
shares
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M14D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y4M9D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M26D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P2Y7M6D
CY2022Q3 dei Document Type
DocumentType
10-Q
CY2022Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q3 dei Entity File Number
EntityFileNumber
001-40483
CY2022Q3 dei Entity Registrant Name
EntityRegistrantName
ALZAMEND NEURO, INC.
CY2022Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1822909
CY2022Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
3500 Lenox Rd NE
CY2022Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1500
CY2022Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
CY2022Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2022Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30326
CY2022Q3 dei City Area Code
CityAreaCode
844
CY2022Q3 dei Local Phone Number
LocalPhoneNumber
722-6303
CY2022Q3 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022Q3 dei Trading Symbol
TradingSymbol
ALZN
CY2022Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q3 dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
95481790 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11527121 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14063811 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
587542 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
349723 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
12114663 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
14413534 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
95812 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102909 usd
CY2022Q3 us-gaap Assets
Assets
12210475 usd
CY2022Q2 us-gaap Assets
Assets
14516443 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1028700 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1162850 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2082 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1028700 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1164932 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1028700 usd
CY2022Q2 us-gaap Liabilities
Liabilities
1164932 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95481790 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95481790 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95481790 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95481790 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
9548 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
9548 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58287091 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57419753 usd
CY2022Q3 alxneuro Note Receivable For Common Stock Related Party
NoteReceivableForCommonStockRelatedParty
-14883295 usd
CY2022Q2 alxneuro Note Receivable For Common Stock Related Party
NoteReceivableForCommonStockRelatedParty
-14883295 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32231569 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29194495 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
11181775 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13351511 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12210475 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14516443 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1375953 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
916408 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1659589 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1389831 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
3035542 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
2306239 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3035542 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2306239 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
1532 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
13628 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1532 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13628 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3037074 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2319867 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97481790 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84588492 shares
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13351511 usd
CY2022Q3 alxneuro Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
867338 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3037074 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
11181775 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2012945 usd
CY2021Q3 alxneuro Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
739622 usd
CY2021Q3 alxneuro Stock Issued During Period Value New Issues2
StockIssuedDuringPeriodValueNewIssues2
2000000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100 usd
CY2021Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1500000 usd
CY2021Q3 alxneuro Stock Issued During Period Value New Issues3
StockIssuedDuringPeriodValueNewIssues3
12911456 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2319867 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
15344256 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3037074 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2319867 usd
CY2022Q3 us-gaap Depreciation
Depreciation
7097 usd
CY2021Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4795 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
867338 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
739622 usd
CY2022Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
237819 usd
CY2021Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
216169 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-136232 usd
CY2021Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
568955 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2536690 usd
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1222664 usd
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2000000 usd
CY2021Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100 usd
CY2021Q3 alxneuro Proceeds From Initial Public Offering Net Of Underwriters Discounts And Commissions And Issuance Costs
ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts
12911456 usd
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14911556 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2536690 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
13688892 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14063811 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1929270 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11527121 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15618162 usd
CY2021Q3 alxneuro Fair Value Of Warrants Issued In Connection With Ipo
FairValueOfWarrantsIssuedInConnectionWithIpo
461877 usd
CY2021Q3 alxneuro Fair Value Of Warrants Issued In Connection With March2021 Securities Purchase Agreement Related Party
FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty
4,799,742
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Cash
Cash
11500000 usd
CY2022Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zPjUqfNQfl64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86D_zuEq5qo7PVub">Accounting Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p>
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28749788 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41562834 shares
CY2022Q2 alxneuro Long Term Debt Average Amount Of Outstanding
LongTermDebtAverageAmountOfOutstanding
14883295 shares
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
451885 usd
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
155880 usd
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
9577 usd
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7176 usd
CY2022Q3 us-gaap Other Receivables
OtherReceivables
9413 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
587542 usd
CY2021Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
349723 usd
CY2022Q3 alxneuro Unamortized Prepaid Expense
UnamortizedPrepaidExpense
452000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
8800000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15700000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.20
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2219700 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1100000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
1.00
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
8800000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14600000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.22
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1777200 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13700000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.23
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1777200 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11514479 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.07
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1777200 usd
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
867338 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
739622 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10149788 shares
CY2022Q3 alxneuro Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
2.90
CY2022Q3 alxneuro Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
10149788 shares
CY2022Q3 alxneuro Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
2.90
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001

Files In Submission

Name View Source Status
0001214659-22-011092-index-headers.html Edgar Link pending
0001214659-22-011092-index.html Edgar Link pending
0001214659-22-011092.txt Edgar Link pending
0001214659-22-011092-xbrl.zip Edgar Link pending
alxneuro-20220731.xsd Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
p9722010q.htm Edgar Link pending
alxneuro-20220731_cal.xml Edgar Link unprocessable
alxneuro-20220731_def.xml Edgar Link unprocessable
alxneuro-20220731_pre.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
p9722010q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
alxneuro-20220731_lab.xml Edgar Link unprocessable